JOHN BEHM: Open Payments
NPI 1528012366 · OWOSSO, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$603 in 39 payments from 10 companies in 2025. Trend: 2023 $488 · 2024 $603 · 2025 $603
Food & beverage: $603
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $187 |
| ABBVIE INC. | 15 | $181 |
| GlaxoSmithKline, LLC. | 3 | $47 |
| Amgen Inc. | 2 | $39 |
| AstraZeneca Pharmaceuticals LP | 2 | $39 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Alkermes, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $18 |
| Exact Sciences Corporation | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
Products named: CAPLYTA, VRAYLAR, TRELEGY ELLIPTA, OTEZLA, Auvelity, REXULTI, QULIPTA, ARISTADA.
Industry payments across MI — which companies pay providers there.
